Nuvectis Pharma initiates phase 1a NXP900 clinical trial
September 13, 2023Research and Development Cancer, Nuvectis Pharma, Oncology, clinical trial
Clinical stage biopharmaceutical company Nuvectis Pharma has announced the initiation of a phase 1a dose escalation clinical study of NXP900, …
FDA approves LimFlow system for patients with CLTI
September 13, 2023Medical Communications CLTI, Devices, FDA, LimFlow
LimFlow SA has announced that the US Food and Drug Administration (FDA) has approved its LimFlow System for the treatment …
NHS-integrated pharmacy app Charac receives £1.2m funding
September 12, 2023Research and Development Charac, Pharmacy, app, digital health, pharmacies
Charac, an NHS-integrated pharmacy app, has raised £1.2m in debt and equity financing from the National Pharmacy Association (NPA) and …
Neurocrine Biosciences begins phase 1 study assessing NBI-1117570 in healthy adults
September 12, 2023Research and Development Neurocrine Biosciences, Neurology, Sosei Heptares, clinical trial
Sosei Heptares has announced that its partner, Neurocrine Biosciences, has initiated its phase 1 first-in-human clinical trial to assess the …
AstraZeneca and Daiichi Sankyo share positive results from DESTINY-Lung02 phase 2 trial
September 11, 2023Medical Communications AstraZeneca, Daiichi Sankyo, Enhertu, NSCLC, Oncology, clinical trial
AstraZeneca and Daiichi Sankyo have announced results from the primary analysis of the DESTINY-Lung02 phase 2 trial, which showed Enhertu’s …
Sandoz announces deal to commercialise biosimilar ustekinumab in Europe and North America
September 11, 2023Research and Development Pharmacy, SB17, Sandoz, commercialisation, ustekinumab
Sandoz has announced that it has entered into a development and commercialisation agreement with Samsung Bioepis, providing Sandoz the exclusive …
CymaBay shares results from phase 3 RESPONSE trial for seladelpar
September 8, 2023Research and Development CymaBay, PBC, Pharmacy, clinical trial, seladelpar
CymaBay Therapeutics has announced positive topline results from its phase 3 RESPONSE study which assessed the safety and efficacy of …
Vaxart shares topline data from phase 2 study of norovirus vaccine candidate
September 8, 2023Research and Development Infections and infestations, Vaccine, Vaxart, norovirus
Vaxart has announced topline data from its phase 2 challenge study which assessed its oral tablet monovalent norovirus vaccine candidate. …
Valneva and Pfizer share positive results from phase 2 trial for Lyme disease vaccine candidate
September 7, 2023Medical Communications Infections and infestations, Pfizer, Vaccine, Valneva, clinical trial, lyme disease
Valneva and Pfizer have announced positive paediatric and adolescent immunogenicity and safety data for their Lyme disease vaccine candidate, VLA15, …
BridgeBio Pharma shares positive feedback from FDA and EMA for phase 3 trial of infigratinib
September 7, 2023Research and Development BridgeBio Pharma, EMA, FDA, Musculo-skeletal disorder, achondroplasia, clinical trial
BridgeBio Pharma has announced positive feedback from the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) on …
Abbott to acquire Bigfoot Biomedical
September 6, 2023Business Services Abbott, Bigfoot Biomedical, Diabetes, acquisition, diabetes
Abbott and Bigfoot Biomedical have announced a definitive agreement for Abbott to acquire Bigfoot, however this transaction is still subject …
Plus Therapeutics initiates part B of phase 1/2a ReSPECT-LM trial for leptomeningeal metastase
September 6, 2023Research and Development Oncology, Plus Therapeutics, clinical trial, leptomeningeal metastase
Plus Therapeutics has announced that the first patient has begun treatment in part B of the ReSPECT-LM phase 1/2a dose …
AbbVie’s Aquipta receives MHRA marketing authorisation
September 5, 2023Sales and Marketing AbbVie, Aquipta, MHRA, Neurology, atogepant, migraines
AbbVie has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted a marketing authorisation for Aquipta (atogepant), …
ACM Biolabs shares positive results from phase 1 SARS-CoV-2 booster vaccine trial
September 5, 2023Research and Development ACM Biolabs, COVID-19, Immunology, SARS-CoV-2, Vaccine, clinical trial
ACM Biolabs has announced positive topline results from its phase 1 trial of ACM-001, an adjuvanted booster vaccine for SARS-CoV-2, …
AstraZeneca’s Calquence approved in China for chronic lymphocytic leukaemia treatment
September 4, 2023Medical Communications AstraZeneca, CLL, China, Oncology, SLL
AstraZeneca has announced that Calquence (acalabrutinib) has been approved in China for the treatment of adult patients with chronic lymphocytic …
Novo Nordisk launches Wegovy in the UK
September 4, 2023Medical Communications NHS, NICE, Novo Nordisk, Obesity, Wegovy, weight loss
Novo Nordisk has today announced that Wegovy (semaglutide injection) is now available in the UK through a controlled and limited …
Genentech shares phase 3 results for ALK-positive early-stage lung cancer treatment
September 1, 2023Research and Development Genentech, NSCLC, Oncology, clinical trials, lung cancer
Roche’s Genentech has announced that the phase 3 ALINA trial assessing Alecensa, compared with platinum-based chemotherapy for the treatment of …
FDA approves new ADHD and BED generics
September 1, 2023Medical Communications BED, FDA, Pharmacy, generic medicines
The US Food and Drug Administration (FDA) has announced that it has approved several first generics of Takeda’s Vyvanse (lisdexamfetamine …
First patient dosed in phase 1 study for chronic hepatitis B treatment
August 31, 2023Medical Communications Chronic Diseases, ISA Pharmaceuticals, ISA104, clinical trial, hepatitis B
ISA Pharmaceuticals has announced that the first patient has been dosed in its phase 1 HEB-PEP study, assessing the use …
Twist Bioscience and Ono Pharmaceutical enter agreement for discovery of novel antibodies
August 31, 2023Research and Development Immunology, Ono Pharmaceutical, Twist Bioscience, antibodies, autoimmune diseases
Twist Bioscience has announced that it has entered a drug discovery agreement with Ono Pharmaceutical for the discovery and development …
Latest content
FibroFind appoints Lee Borthwick as CEO
